Interstitial wires releasing diffusing alpha emitters combined with chemotherapy improved local tumor control and survival in squamous cell carcinoma-bearing mice

Cancer

Volumn 115, Issue 8, 2009, Pages 1791-1801

  Cooks, Tomer ^a   Arazi, Lior ^a   Efrati, Margalit ^a   Schmidt, Michael ^a   Marshak, Gideon ^a,c   Kelson, Itzhak ^a,b   Keisari, Yona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Althera Medical   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

Alpha radiation; Chemoradiotherapy; Cisplatin; Squamous cell carcinoma

Indexed keywords

CISPLATIN; RADIUM 224; STAINLESS STEEL;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIFFUSING ALPHA EMITTER RADIATION THERAPY; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ALPHA PARTICLES; ANIMALS; APOPTOSIS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; RADIUM; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65249099618     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24191     Document Type: Article

References (37)

1. Curran WJ. New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology. 2002;63 (suppl 2):29-38.
2. Spalding AC, Lawrence TS. New and emerging radiosensitizers and radioprotectors. Cancer Invest. 2006;24:444-456.
3. Sharma VM, Wilson WR. Radiosensitization of advanced squamous cell carcinoma of the head and neck with cisplatin during concomitant radiation therapy. Eur Arch Otorhinolaryngol. 1999;256:462-465.
4. Awada A, Ismael G. The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neck. Curr Opin Oncol. 2007;19: 177-179.
5. Hao D, Ritter MA, Oliver T, Browman GP. Platinum- based concurrent chemoradiotherapy for tumors of the head and neck and the esophagus. Semin Radiat Oncol. 2006;16:10-19.
6. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005;(3):CD002225.
7. Brizel DM, Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol. 2006;24:2612-2617.
8. Thatcher N, Faivre-Finn C, Blackhall F, Anderson H, Lorigan P. Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer. Clin Cancer Res. 2005;11(13 pt 2):5051s-5056s.
9. Warnke U, Rappel C, Meier H, et al. Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guano- sine 5'-monophosphate O6-N7 chelation. Chembiochem. 2004;5:1543-1549.
10. Scagliotti G. Optimizing chemotherapy for patients with advanced non-small cell lung cancer. J Thorac Oncol. 2007;2(suppl 2):S86-S91.
11. Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest. 2006;24:593-600.
12. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. JClin Oncol. 2006;24:2644-2652.
13. Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist. 2005;10:215-224.
14. Coderre JA, Turcotte JC, Riley KJ, Binns PJ, Harling OK, Kiger WS, 3rd. Boron neutron capture therapy: cellular targeting of high linear energy transfer radiation. Technol Cancer Res Treat. 2003;2:355-375.
15. Couturier O, Supiot S, Degraef-Mougin M, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging. 2005;32:601-614.
16. Forman JD, Yudelev M, Bolton S, Tekyi-Mensah S, Maughan R. Fast neutron irradiation for prostate cancer. Cancer Metastasis Rev. 2002;21:131-135.
17. Boeckman HJ, Trego KS, Turchi JJ. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of non- homologous end joining. Mol Cancer Res. 2005;3:277-285.
18. Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol. 2006;16:2-9.
19. Hall EJ. Radiobiology for the Radiologist, 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.
20. International Commission for Radiological Protection (ICRP). Age-dependent Doses to Members of the Public from Intake of Radionuclides: Part 2 Ingestion Dose Coefficients. ICRP Publication 67. Oxford, United Kingdom: Pergamon Press; 1993.
21. Pouget J-P, Mather SJ. General aspects of the cellular response to low- and high-LET radiation. Eur JNucl Med. 2001;28:541-561.
22. Abend M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol. 2003;79:927-941.
23. Cherel M, Davodeau F, Kraeber-Bodere F, Chatal JF. Current status and perspectives in alpha radioimmunotherapy. Q J Nucl Med Mol Imaging. 2006;50:322-329.
24. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451-4459.
25. Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I. Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters. Phys Med Biol. 2007;52:5025-5042.
26. Cooks T, Arazi L, Schmidt M, Marshak G, Kelson I, Keisari Y. Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms. Int J Cancer. 2008;122:1657-1664.
27. Murdoch D. Standard, and novel cytotoxic and molecular- targeted, therapies for HNSCC: an evidence-based review. Curr Opin Oncol. 2007;19:216-221.
28. Blank M, Lavie G, Mandel M, et al. Antimetastatic activity of the photodynamic agent hypericin in the dark. Int J Cancer. 2004;111:596-603.
29. Ziegler JF. Stopping and ranges in matter (SRIM). Available at http://www.srim.org. Accessed on January 25, 2009.
30. Carlsson J, Eriksson V, Stenerlow B, Lundqvist H. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy. Eur J Nucl Med Mol Imaging. 2006;33:1185-1195.
31. Fields MT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once- versus twice-weekly 2'2'- difluoro-2'-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys. 2000;47:785-791.
32. Rosenthal DI, Lee JH, Sinard R, et al. Phase I study of paclitaxel given by 7-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2001;19:1363-1373.
33. Varveris H, Mazonakis M, Vlachaki M, et al. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck. Oncol Rep. 2003;10:185-195.
34. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081-2086.
35. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000;18:1458-1464.
36. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. MACH-NC Collaborative Group Metaanalysis of chemotherapy on head and neck cancer. Lancet. 2000;355:949-955.
37. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.